Long-Term Outcomes of Mitral Valve Replacement in Patients Weighing Less Than 10 Kg

Haoyong Yuan  
The second xiangya hospital of central south university

Zhongshi Wu  
The second xiangya hospital of central south university

Ting Lu  
The second xiangya hospital of central south university

Yilun Tang  
The second xiangya hospital of central south university

Jinlan Chen  
The second xiangya hospital of central south university

Yifeng Yang  
The second xiangya hospital of central south university

Can Huang (huangcan413@csu.edu.cn)  
The second xiangya hospital of Central South University  https://orcid.org/0000-0002-6401-3914

Research article

Keywords: mitral valve replacement, pediatric, mechanical prosthesis, lower cardiac output syndrome

DOI: https://doi.org/10.21203/rs.3.rs-127858/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The outcomes of mitral valve replacement (MVR) in pediatrics especially in the patients weighing less than 10kg are not always favorable. This study aimed to measure long-term outcomes of MVR in our institution.

Methods: Nine young children weighing less than 10 kg underwent MVR with mechanical prostheses from November 2006 to April 2019 were enrolled in this retrospectively study. Kaplan–Meier survival analysis was used for the prediction of freedom from death and adverse events. Chi-square test was performed to compare outcomes for patients based on the ratio of mechanical prosthesis and weight. 14 related literatures were also reviewed to support our study.

Results: All patients received bileaet mechanical prostheses. The surgical technique varied among the patients with prostheses implanted in the intra-annular (n = 5), supra-annular (n=1), or with a Dacron conduit segment in the supra-annular position(n = 3). The valve size/weight ratio ranged from 2.11 to 5.00. After a mean follow-up period of 80.67 ± 63.37 months, the survival rate was 66.67%. One (11.1%) patient underwent an immediate revision MVR after initial MVR for the periprosthetic leak. No patients required surgical reintervention for the development of left ventricular outflow tract obstruction or permanent pacemaker placement during long-term follow-up.

Conclusions: The tailored surgical strategy utilized for MVR in infants resulted in reliable valve function and excellent survival. Although revision is inevitable due to somatic growth, the bilealet mechanical prostheses displayed appropriate durability.

Visual Abstract

- Key question (120 characters including spaces)
  What should we do for patients with mitral valve diseases weighing less than 10 kg?

- Key findings (120 characters including spaces)
  Mechanical valve prostheses might be a good choice.

- Take-home message (140 characters including spaces)
  MVR in infants resulted in reliable valve function and excellent survival. The mechanical prostheses displayed appropriate durability.

Introduction

Mitral valve diseases in children are complex and are always accompanied by various cardiac anomalies, making surgical treatment challenging[1]. Although the techniques of mitral valve repair (MVP) in children have been well established and provide acceptable long-term outcomes, mitral valve replacement (MVR) remains the sole surgical alternative.[2] Because of early calcification and short durability of bio-prostheses, mechanical mitral valve replacement (mMVR) is the most common choice for the pediatric population, especially for neonates and infants[3]. In these cases, a larger-sized prosthesis valve is implanted into the small annulus, possibly causing high mortality, left ventricular outflow obstruction (LVOTO), complete atrioventricular block postoperatively, pulmonary vein stenosis, low valve durability and need for anticoagulant management postoperatively[4]. During the past decades, many techniques and prosthesis have been employed to treat mitral valve diseases in infants and the outcomes of the MVR in the patients weighing 10 kg are not always favorable. To better understand the optimal approach to this complex problem, we retrospectively examined our experience with children less than 3 years old and weighing less than 10 kg who underwent mMVR.

Patients And Methods

Patients

We considered all patients weighing 10 kg or less and younger than 3 years old who underwent MVR with mechanical prostheses at the Second Xiangya Hospital of Central South University in China between November 2006 and April 2019. Data were acquired from hospital records and the institute's cardiac database and were analyzed retrospectively. This study was approved by the Institutional Ethics Committee and written informed consent was obtained from parents or guardians before surgery to allow the use of their data.

Surgical Technique

All patients underwent median sternotomy and standard cardiopulmonary bypass under moderate hypothermia (range 28 to 32 °C). The mitral valve was exposed through an "L" shaped atrial septectomy (from the entrance of superior vena cava to the front of the coronary sinus). mMVR was performed after unsuccessful mitral valvuloplasty or when the valve was judged to be unsuitable for repair. The posterior leaflet tissue and subvalvular apparatus of the mitral valve were preserved wherever possible. In patients with infective endocarditis, all valve tissue was excised and sent for bacterial cultures. Valves were implanted in either a supra- or intra-annular position; supra-annular valves were sometimes tilted either anteriorly or posteriorly to optimize positioning. When doing the skirt super-annular MVR, the Dacron conduit was interrupt sutured in the annular position and then
the mechanical prosthesis was running sutured to the conduit (Fig. 1 and Video). Three patients underwent MVR concomitant with the repair of the associated cardiac abnormalities, including ventricular septal defect (VSD) closure (n = 1), ligation of patent ductus arteriosus (PDA) (n = 1), correction of coarctation of the aorta (n = 1). Intraoperative transesophageal echocardiography was used to confirm adequate prosthetic valve function in all cases.

**Follow-up**

Postoperatively, anticoagulation was obtained using sodium warfarin, aiming at an international normalized ratio (INR) of 2.0–2.5. Temporary anticoagulation with intravenous heparin was also used during the 24 hours after the surgery and invasive procedures, aiming at an activated partial thromboplastin time (APTT) of 1.5–2.0 times above baseline.

**Statistical analysis**

The Statistical Package for Social Sciences (SPSS) version 22.0 (IBM) was used for all data analyses. Descriptive statistical analysis was undertaken using continuous data presented as median and interquartile range (IQR) or mean ± standard deviation and categorical variables as raw data and/or percentages. Kaplan–Meier survival analysis was used for the prediction of freedom from death and adverse events. Chi-square test was performed to compare outcomes for patients based on the ratio of mechanical prosthesis and weight.

**Result**

**Demographics**

A total of nine pediatric patients were included in this study; there were three boys and six girls in this cohort. The ages of seven patients were less than 1 year at the initial mMVR procedure. The mean age at the initial mMVR was 11.88 ± 11.29 months (range 1 months to 32 months) and mean body weight was 6.83 ± 2.56 kg (range 4.0 to 9.5 kg). Two patients weighing less than 5 kg were diagnosed with severe congenital mitral valve regurgitation and stenosis and were treated with ventilator-assisted respiration before the operation. Mitral valve regurgitation was found in four patients after the AVSD repair, one of which was accompanied by fungal endocarditis after the partial AVSD repair. Three patients were diagnosed with severe mitral valve regurgitation with coarctation (CoA), patent ductus arteriosus, or ventricular septal defect (Table 1). Four (44.4%) patients underwent previous cardiosurgical procedures, of which three underwent partial or complete AVSD repair and one underwent VSD closure and MVP.

| NO. | Sex | Age (months) | Weight (kg) | Diagnosis | Procedure | VALVE (SIZE) | Ratio | redo | Clamping | Bypass | Ventilation time (hour) | ICU Stay (day) | PG 1 week post | Early Death |
|-----|-----|--------------|-------------|-----------|-----------|-------------|-------|------|----------|--------|------------------------|---------------|---------------|-------------|
| 1   | F   | 9            | 9           | MR, Post CAVSD Repair | SSMVR    | 19          | 2.11  | N    | 173      | 285    | 66                      | 3.3           | 8             | N           |
| 2   | M   | 3            | 5.5         | MR, VSD | SMVR | 19          | 3.45  | Y    | 125      | 185    | 336                    | 14            | Y             | N           |
| 3   | F   | 3            | 4.7         | MS, MR | SSMVR | 19          | 4.0   | N    | 104      | 121    | 124                    | 10            | 12            | N           |
| 4   | F   | 1            | 3.8         | Post MVP, MR | MVR | 19          | 5     | N    | 160      | 209    | 48                     | 2             | Y             | N           |
| 5   | F   | 12           | 7           | IE, MR, Post PAVSD Repair | MVR | 21          | 3     | N    | 56       | 95     | 504                    | 89            | Y             | N           |
| 6   | F   | 21           | 9           | MR, PDA | MVR | 25          | 2.7   | N    | 33       | 57     | 19                     | 1.8           | 12            | N           |
| 7   | M   | 2            | 4           | MS, MR | SSMVR | 16          | 4     | N    | 124      | 171    | 384                    | 20            | 12            | N           |
| 8   | F   | 32           | 9.5         | MR, Post PAVSD Repair | MVR | 25          | 2.6   | N    | 104      | 155    | 72                     | 7             | 10            | N           |
| 9   | M   | 24           | 9           | MR, CoA | MVR | 25          | 2.7   | N    | 56       | 111    | 120                    | 8             | 9             | N           |

Age (months), Clamping and Bypass (minute), Ventilation time (hour), ICU Stay (day), Weight (kg), Size (mm), PG (mmHg), F = Female, M = Male, N = NO, Y = Yes, Ratio = valve size/weight, Redo = Reintervention after initial MVR.

MR = Mitral valve regurgitation, MS = Mitral valve stenosis, VSD = Ventricular septal defect, PDA = Patent duct arteriosus, IE = infective endocarditis, PAVSD = Partial atrioventricular septal defect, CAVSD = Complete atrioventricular septal defect, CoA = Coarctation, MVP = Mitral valve repairment, MVR = Mitral valve replacement, SMVR = Supra-annul mitral valve replacement, SSMVR = Skirt supra-annul mitral valve replacement, PG = Pressure gradient

**Surgical technique**
All patients received bileaet mechanical prosthetic valves (ATS Medtronic, Minneapolis, Minnesota), with three receiving mitral prostheses and six receiving inverted aortic prostheses. Surgical technique varied between patients with valves implanted intra-annularly (n = 5), supra-annularly (n = 1), or supra-annularly with a tilt (n = 3). The valve size/weight ratio ranged from 2.11 to 5.00 (average 3.28 ± 0.91) and there is significant difference between the ratio over 3 and below (p = 0.03) for early mortality (Fig. 2 and Table 2). The cardiopulmonary bypass time was 154.33 ± 68.25 min (range 57 min to 285 min), and the aorta clamp time was 103.89 ± 47.94 min (range 33 min to 173 min). At our institution, patient INRs were strictly monitored at outpatient hematology clinics during follow-up; there were no emergency operations for acute valve thrombosis or a significant event in other series.

### Early and Long-term Follow-up Outcomes

Three patients died 3 months postoperatively; the early survival rate was 66.67% One died from mycotic endocarditis and the other two died from low cardiac output syndrome (Fig. 3). One underwent redo MVR because of a perivalvular leak. The postoperative intensive care unit (ICU) stay ranged from 1.8 to 89 days with a median of 8 days. The median duration of postoperative ventilation was 120 hours ranged from 19 to 504 hour (Table 3). Survival was 100% with the other six patients alive after a mean follow-up of 80.67 ± 63.37 months. The transvalvular gradient was 10.5 ± 1.76 mmHg (range 8 to 12) and the peak gradient of LVOT was 5.00 ± 0.64 mmHg. No patients required surgical reintervention for the development of left ventricular outflow tract obstruction or permanent pacemaker placement during long-term follow-up (Table 4).

### Discussion

MVP is considered to be the current standard of care for the treatment of children with mitral valve abnormalities. Unfortunately, there are certain pediatric patients who will need an MVR instead of an unsuccessful MVP; difficulties for both decision-making and treatment options may arise[5]. The most common indications for MVR in children include rheumatic disease, endocarditis, mitral stenosis in Shone’s syndrome or failed auriculoventricular (AV) canal repair. In our studies, over 50% of the patients were diagnosed with mitral valve disease with infective endocarditis and failed auriculoventricular septal repair. Bioprostheses were not the appropriate choices for MVR in children and infants due to the lack of durability and unavailability of small-sized prostheses. The pulmonary autograft replacement of the MV and Contegra conduit were employed to treat pediatric patients with small annular to avoid long-term anticoagulation. However, because of accelerated degeneration and calcification, these techniques require long-term follow-up[6, 7]. The Ross II procedure changed one-valve problem to two-valve problems, similar to the Ross procedure, possibly

---

Table 2

| Ratio          | Death | Survival | P value |
|----------------|-------|----------|---------|
| Ratio ≥ 3      | 3     | 2        | P = 0.03|
| Ratio < 3      | 0     | 4        |         |

Table 3

| Age at operation | 11.88 ± 11.29 months (range 1 months to 32 months) |
|------------------|---------------------------------------------------|
| Weight at operation | 6.83 ± 2.56 kg (range 4.0 to 9.5 kg)               |
| Interval from original ration | 80.67 ± 63.37 months                               |
| The cardiopulmonary bypass time | 154.33 ± 68.25 min (range 57 min to 285 min)       |
| The aorta clamp time | 103.89 ± 47.94 min (range 33 min to 173 min)       |
| Duration of ventilation | Median 120 hours (ranged from 19 to 504 hour)     |
| Duration of ICU stay | Median 8 days (ranged from 1.8 to 89 days)        |

Table 4

| Patients | Follow Up | PG(LVOT) | PG(MV) | mPAP |
|----------|-----------|----------|--------|------|
| 1        | 8         | 5        | 8      | 20   |
| 3        | 32        | 5        | 11     | 16   |
| 6        | 108       | 6        | 12     | 20   |
| 7        | 36        | 5        | 12     | 18   |
| 8        | 144       | 5        | 11     | 17   |
| 9        | 156       | 4        | 10     | 16   |

Follow up (months), MV = Mitral valve, PG = Pressure gradient, LVOT = left ventricular outflow tract, mPAP = mean pulmonary artery pressure
resulting in early regurgitation due to the lack of valve commissural support and higher trans-valvar pressure differences. Considering their better durability, availability, and hemodynamic performance, mechanical valves are the preferred mitral valve substitute in children.

Historically, MVR in infants has been associated with significant morbidity and mortality and long-term survival is lower than that of infant MV repair[8]. Consequently, surgical techniques and strategies have evolved to optimize outcomes. The reported operative mortality for MVR in infants is 5–30% and the 10- and 30-year survival for these patients has been recently reported up to 75%[5] (Table 5). Heart block requiring pacemaker implantation, endocarditis, thrombosis, stroke, an increased ratio of prosthetic size/weight and supra-annular position were all found to be statistically significant predictors of early mortality[9]. In our institute, the early mortality is 33.33% with 100% survival after discharge. Among the three patient deaths, one died from a fungal infection and two died from low cardiac output syndrome. Although there were a relatively small number of deaths in our study, we found that smaller annulus, heart failure before the procedure and fungal infections were risk factors for short-term mortality. Previous studies demonstrated that age less than 2 years old at MVR was a risk factor for operative mortality[10]. Rai et al. found that there was no significant difference in survival between patients aged less than 2 years and patients aged 2 to 18 years, and age less than 2 years remained a risk factor for reoperation but not for mortality[11]. Bileaflet mechanical prostheses from ATS Medtronic (Minneapolis, Minnesota) were implanted in nine patients in our study. Because the smallest size of the available mechanical mitral valve in our institute is 25 mm, six patients were implanted with mechanical aortic valve prostheses. Due to the low profile, excellent hemodynamics and good durability, a bileaflet mechanical valve is the prosthesis of choice in the mitral position in children[12]. Size mismatch between the mechanical prosthesis and mitral valve annulus is considered to be a risk factor for operative mortality[13]. Caldarone et al. showed that the prosthesis size–to–patient body weight ratio was < 2 and 1-year survival rate was 91%; however, the survival rate was only 61% when the value was > 4 and only 37% when the ratio was < 5[1]. In our study, the ratio ranged from 2.1 to 5 and the ratios of the deceased patients were all over 3. This suggests that an appropriate mechanical prosthesis is essential for successful MVR in children. Prosthesis size should be carefully chosen based on the body weight, age, and mitral valve annular size of an individual patient.

### Table 5

| Studies                              | Cases | Age               | Follow up          | Survival rate | Free from Redo MVR |
|--------------------------------------|-------|-------------------|--------------------|---------------|--------------------|
| Mater, Kathryn. 2019. Australia⁹     | 22    | Mean age 6.8 ± 4.1 months | 6.2 ± 4.4 years   | 100%          | 86.1% at 1 years, 80.7% at 5 years and 21.2% at 10 years |
| Raffaele Giordano. 2015. Italy²      | 7     | Mean age 13.3 ± 11.2 months | 67.1 ± 34.8 months | 100%          | 71.4%              |
| Christopher A. Caldarone 2015. USA³  | 139   | Mean age 1.9 ± 1.4 years | Median 6.2 years  | 74%           |                    |
| Jiyong Moon. 2015. Japan²⁰          | 18    | Mean age 4.0 ± 1.8 months | 4.5 ± 3.8 years   | 89.1%         | 57.8% at 10 years  |
| John W. Brown. 2012. USA¹⁸          | 97    | Median age 8 years | 12.8 ± 10.1 years | 71%           | 94% at 1 year, 82% at 5 years, 71% at 10 years, and 63% at 20 and at 35 years |
| Hyung-Tae Sim. 2012. Korea²¹         | 19    | Mean age 7.6 ± 5.5 years | 76 ± 56 months    | 100%          | 94.7 ± 5% at 10 years |
| Daniela Y. Rafii. 2011. USA¹¹        | 18    | Median age 1.2 years | Median 5.4 years  | 82%           | 69% at 5 years and 40% at 10 years |
| Kirk R. Kanter. 2011. USA²²         | 15    | Mean age 337 ± 412 days | 4.3 ± 2.8 years, 4.1 ± 3.7 years | 84%           | 69% at 5 years and 21% at 10 years |
| BahaaldinAlsoufi. 2010. Canada²²    | 79    | Median age 24 months | Over 30 years     | 56%           | 72% at 5 years and 45% at 10 years |
| ElfSeda Selamet Tiemey. 2008. USA⁴   | 118   | Median age 16.3 months | Over 30 years     | 56%           | 72% at 5 years and 45% at 10 years |
| J. S. Sachweh. 2007. Germany²³      | 17    | Mean age 4.3 ± 4.3 years | 9.1 ± 6.6 years   | 94.1%         | 93.4% at 1 year 89.0% at 5 and 10 years |
| Wolfram Beierlein. 2007. UK²⁴       | 54    | Median age 3.0 years | Median 9.2 years  | 33%           | 45.3% at 5 years and 17.3% at 10 years |
| Hunaid A. Vohra. 2007. UK¹²         | 24    | Mean age 1.4 ± 1.3 years | Median 7.5 years  | 75.7%         |                    |
| Naoki Wada. 2005. Japan²⁵           | 18    | Mean age 1.02 ± 0.72 years | 3.3 ± 3.5 years  | 68.9%         | 87.1% at 5 years and 69.6% at 10-years |
Multiple surgery techniques were employed in the MVR. The appropriate available mechanical valve was implanted in the annulus if the size matched. Because of the link between the mechanical valve size and freedom from redo MVR, a large mechanical prosthesis was implanted to the smaller annulus, possibly causing atrioventricular block and left ventricle outflow tract obstruction related to valve impingement on surrounding cardiac structures[14]. In the neonate or infant with a small native annulus, implantation of commercially available prosthetic valves in the annular position can be problematic. Placing the prosthesis in a supra-annular position is an alternative when a more traditional annular implantation is not possible. The prosthetic valve was implanted with interrupted pledget polyester sutures with the pledgets on the atrial side of the prosthesis[15]. Previous publications suggested that the early results with supra-annular MVR in children were discouraging and identified it as a risk factor for early mortality because of the reduction of LA volume and compliance and aneurysm formation in the segment of LA between the prosthesis and the annulus[2]. One of our patients had valves implanted with a tilt, similar to that described by Moon and colleagues[15], which involved suturing part of the valve onto the native annulus and the remainder to the left atrial wall or atrial septum. The prosthesis was thereby implanted supra-annularly with a tilt either anteriorly or posteriorly to prevent impingement on the LVOT, pulmonary vein orifices, and conduction tissue. Two weeks later, the patient underwent redo MVR for the periprosthetic leakage and died for acute low cardiac output syndrome. We suggest that implanting the prosthesis supra-annularly with a tilt may have caused the periprosthetic leakage and the immediate redo MVR. Three patients had Dacron Hemashield (Meadow Medicals, Inc, Oakland, NJ) with interrupted sutures sewn to the native valve annulus, after which the prosthetic valve was sewn with running sutures into the conduit. We employed the Dacron conduit that would be softer and provide better hemodynamics than the Gore-Tex conduit. The prosthetic valves were implanted to the conduit follow suturing the pipe to the annulus, which may provide convenience for the surgeon to implant a larger valve in a smaller space, also reducing the occurrence of periprosthetic leakage[16]. The technique of intermittent suture would preserve the growth potential and may provide the possibility for the replacement of a larger mitral valve in the future. The mitral valve on the annulus will inevitably lead to the reduction of the left atrium content, possibly leading to pulmonary vein obstruction or even pulmonary hypertension. In our case, we did not find the existence of pulmonary hypertension. We believe that the larger left atrium has sufficient space for buffering and grasping the height of the Dacron conduit that can effectively avoid this complication.

Redo valve replacement is inevitable following infant MVR because of somatic growth. The duration has been reported to be 8.6 ± 6.6 years in children < 5 years of age at initial MVR and 7.3 years following infant MVR[17]. The most common reported indication for early redo valve replacement is excessive pannus formation, particularly in infants and young children. valve type, size, and positioning were thought to optimize the longevity of the implanted prosthesis and maximize time until redo MVR[18]. As presented in our follow-up results, the transvalvular gradients of the implanted mechanical aortic valve and mitral valve demonstrated no significant differences. Studies indicated that choosing a mechanical valve larger than 19 mm could considerably delay the redo MVR[5], due to valve size ≥ 19 mm. There were no redo MVRs for somatic growth in our cohort.

There are several limitations to this study. First, it was a single-centre study, and therefore may be subject to selection bias. For this reason, we instituted strict inclusion and exclusion criteria. Multi-centre studies are needed to validate our findings. Besides that, study is limited by its retrospective design and the relatively small patient population.

Conclusion

In terms of long-term outcomes, MVR is an adequate remedial procedure for MVP in infants and young children whose weight is less than 10 kg. The ratio between the size of mechanical prosthesis and weight and mycotic endocarditis are risk factors for patients undergoing mechanical MVR. The size of mechanical vale over 19 mm can avoid redoing MVR for 10 years or more. The skirt super-annular may reduce the mortality associated with MVR with a mismatched ratio.

Abbreviations

Mitral Valve Repair (MVP)
Mitral Valve Replacement (MVR)
Mechanical Mitral Valve Replacement (mMVR)
Supra-Annul Mitral Valve Replacement (SMVR)
Skirt Supra-Annul Mitral Valve Replacement (SSMVR)
Left Ventricular Outflow Obstruction (LVOTO)
International Normalized Ratio (INR)
Activated Partial Thromboplastin Time (APTT)
Statistical Package for Social Sciences (SPSS)
Interquartile Range (IQR)
Intensive Care Unit (ICU)
Auriculoventricular (AV)
Mitral Valve Regurgitation (MR)
Mitral Valve Stenosis (MS)
Ventricular Septal Defect (VSD)
Patent Duct Arteriol (PDA)
Infective Endocardiatis (IE)
Partial Artroventricular Septal Defect (PAVSD)
Complete Artroventricular Septal Defect (CAVSD)
Coarctation (CoA)
Pressure Gradient (PG)
Mean Pulmonary Artery Pressure (mPAP)

Declarations

Ethical Approval and Consent to participate

This study was approved by the Institutional Ethics Committee and written informed consent was obtained from parents or guardians before surgery to allow the use of their data.

Consent for publication

Written informed consent for publication was obtained from all participants

Availability of supporting data

The data sets supporting the results of this article are included within the article and its additional files.

Competing interests

There's no completing interests for this study.

Funding

1. National Natural Science Foundation of China (81771991);
2. National key research and development project (2016YFC1101002)
3. Major Scientific and Technological Projects for collaborative prevention and control of birth defects in Hunan Province: 2019SK1010

Authors' contributions

Dr Can Huang, Zhongshi Wu, and Haoyong Yuan developed the idea of the study, participated in its design and coordination and helped to draft the manuscript. Ting Lu and Yilun Tang contributed to the acquisition and interpretation of data. Yifeng Yang and Jinlan Chen provided critical review and substantially revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. Caldarone, C.A., et al., Long-term survival after mitral valve replacement in children aged &lt;5 years: a multi-institutional study. Circulation, 2001. 104(12 Suppl 1): p. I143-7.
2. Giordano R, et al. Supra-Anular Mitral Valve Implantation in Very Small Children. J Card Surg. 2015;30(2):185–9.
3. Alsoufi B, et al. Aortic and mitral valve replacement in children: is there any role for biologic and bioprosthetic substitutes? Eur J Cardiothorac Surg. 2009;36(1):84–90. discussion 90.
4. Ibezim C, et al. Outcomes of Mechanical Mitral Valve Replacement in Children. The Annals of Thoracic Surgery. 2019;107(1):143–50.
5. Henaine R, et al. Valve replacement in children: A challenge for a whole life. Arch Cardiovasc Dis. 2012;105(10):517–28.
6. Brizard CPMM, et al. Intra-annular mitral valve replacement in neonates and infants. Journal of Thoracic Cardiovascular Surgery The. 2015;149(1):390–2.e1.
7. Blitzer D, Herrmann JL, Brown JW. Pulmonary Autograft Mitral Valve Replacement (Ross II): Long-Term Follow-Up of a US Center. World Journal for Pediatric Congenital Heart Surgery. 2018;9(6):645–50.
8. Selamet Tierney ES, et al. Mitral valve replacement in infants and children 5 years of age or younger: Evolution in practice and outcome over three decades with a focus on supra-annular prosthesis implantation. The Journal of Thoracic Annular Cardiovascular Surgery. 2008;136(4):954–61.e3.
9. Mater K, et al. Patient-Specific Approach to Mitral Valve Replacement in Infants Weighing 10 kilograms or less. World Journal for Pediatric Congenital Heart Surgery. 2019;10(3):304–12.
10. Alexiou C, et al. Mitral valve replacement with mechanical prostheses in children: improved operative risk and survival. Eur J Cardiothorac Surg. 2001;20(1):105–13.
11. Rafii DY, et al. Age Less Than Two Years Is Not a Risk Factor for Mortality After Mitral Valve Replacement in Children. The Annals of Thoracic Surgery. 2011;91(4):1228–34.
12. Vohra HA, et al. Predicting the performance of mitral prostheses implanted in children under 5 years of age. Eur J Cardiothorac Surg. 2006;29(5):688–92.
13. Ackermann K, et al. Replacement of the systemic atrioventricular valve with a mechanical prosthesis in children aged less than 6 years: late clinical results of survival and subsequent replacement. J Thorac Cardiovasc Surg. 2007;134(3):750–6.
14. Masuda M, et al. Late results after mitral valve replacement with bileaflet mechanical prosthesis in children: evaluation of prosthesis-patient mismatch. The Annals of Thoracic Surgery. 2004;77(3):913–7.
15. Moon J, et al. Clinical outcomes of mitral valve replacement with the 16-mm ATS advanced performance valve in neonates and infants. Ann Thorac Surg. 2015;99(2):653–9.
16. Yamauchi S, et al. Supra-Annular Mitral Valve Replacement in an Infant With Infective Endocarditis. Ann Thorac Surg. 2018;105(1):e27–9.
17. Kanter KR, Forbess JM, Kirshbom PM. Redo Mitral Valve Replacement in Children. The Annals of Thoracic Surgery. 2005;80(2):642–6.
18. Brown JW, et al. Evolution of Mitral Valve Replacement in Children: A 40-Year Experience. The Annals of Thoracic Surgery. 2012;93(2):626–33.
19. Moon J, et al. Clinical Outcomes of Mitral Valve Replacement With the 16-mm ATS Advanced Performance Valve in Neonates and Infants. The Annals of Thoracic Surgery. 2015;99(2):653–9.
20. Sim H, et al. Mitral Valve Replacement Using Mechanical Prostheses in Children: Early and Long-Term Outcomes. Pediatr Cardiol. 2012;33(4):639–45.
21. Kanter KR, Kogon BE, Kirshbom PM. Supra-Annular Mitral Valve Replacement in Children. The Annals of Thoracic Surgery. 2011;92(6):2221–9.
22. Sachweh JS, et al. Mechanical aortic and mitral valve replacement in infants and children. Thorac Cardiovasc Surg. 2007;55(3):156–62.
23. Beierlein W, et al. Long-term follow-up after mitral valve replacement in childhood: poor event-free survival in the young child. Eur J Cardiothorac Surg. 2007;31(5):860–5.
24. Wada N, et al. Mitral valve replacement in children under 3 years of age. The Japanese Journal of Thoracic Cardiovascular Surgery. 2005;53(10):545–50.